2020
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.Peer-Reviewed Original ResearchMeSH KeywordsGlioblastomaImmunotherapyLab-On-A-Chip DevicesProgrammed Cell Death 1 ReceptorTumor MicroenvironmentConceptsProgrammed cell death protein 1Immunosuppressive tumor microenvironmentTumor-associated macrophagesTumor microenvironmentCD163+ tumor-associated macrophagesPD-1/PD-L1 immune checkpointCSF-1R inhibitor BLZ945Molecularly distinct GBM subtypesCell death protein 1Anti-PD-1 immunotherapyT cell functionNivolumab efficacyImmunotherapy efficacyImmune checkpointsImmune signaturesImmunosuppressive mechanismsT cellsM2-TAMsCo-administeredGlioblastoma patientsIL-10CSF-1RCSF-1ImmunotherapyProneural glioblastoma
2018
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz S, Cabrera L, Hastie D, Huang R, Unadkat P, Rinne M, Nayak L, Lee E, Reardon D, Wen P. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology 2018, 91: e1355-e1359. PMID: 30171077, DOI: 10.1212/wnl.0000000000006283.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabBrain NeoplasmsFemaleGliomaHumansMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsRecurrent high-grade gliomaHigh-grade gliomasRetrospective observational studySalvage therapySurvival benefitSingle-institution retrospective observational studyPD-1 blocking antibodiesObservational studyPD-1 inhibitionProgression-free survivalClass IV evidenceConcurrent bevacizumabAntibody nivolumabPD-1Median survivalClinical benefitImproved survivalNivolumabPembrolizumabAdult patientsBevacizumabIV evidenceClinical trialsPatient populationPatients